BofA raises target for HUTCHMED stock from USD 16.00 to USD 18.00

Published on 10/15/2026 at 19:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 25, 2026, HUTCHMED presents lung cancer data. HUTCHMED stock costs EUR 12.35 at Lang & Schwarz on October 15, 2026 at 7:39 p.m. CEST.

Analyst targets and clinical dates

BofA moved its HUTCHMED target from USD 16.00 to USD 18.00 on September 21, 2026.
HUTCHMED will present SAFFRON data on October 25, 2026, and SANOVO data on October 26, 2026.
HUTCHMED stock costs EUR 12.35 at Lang & Schwarz on October 15, 2026 at 7:39 p.m. CEST.
HUTCHMED had a USD 2.4 billion market capitalization and a price-to-earnings ratio of 147.68 on October 15, 2026.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (China) Limited (ISIN US44842L1035) saw BofA raise its price target from USD 16.00 to USD 18.00 on September 21, 2026. The new target stood 29.87 percent above HUTCHMED's USD 13.86 Nasdaq price at 1:46 p.m. ET on October 15, 2026. HCM was up 2.78 percent from USD 13.48 at that time. The euro quotation was EUR 12.35 at Lang & Schwarz on October 15, 2026 at 7:39 p.m. CEST.

Target leaves room above Nasdaq price

According to Moomoo, BofA analyst Alec Stranahan kept a Buy rating and lifted the target from USD 16.00 to USD 18.00. The change leaves the target 29.87 percent above the Nasdaq price of USD 13.86, a gap that gives the analyst view a clear numerical anchor.

Two clinical dates arrive in October

The next scheduled company-related dates are October 25 and October 26, 2026. A release dated September 23, 2026, carried by StockTitan, said HUTCHMED would present SAFFRON results at a Presidential Symposium on October 25 and SANOVO results in a Proffered Paper session on October 26. The Madrid congress runs from October 23 to October 27, 2026.

Price position and valuation

HUTCHMED's Nasdaq price of USD 13.86 sat between its USD 9.77 52-week low and USD 16.33 52-week high on October 15, 2026. The stock was 15.14 percent below its high and 41.86 percent above its low. Its USD 2.4 billion market capitalization and 147.68 price-to-earnings ratio put valuation figures alongside the target discussion.

Comparison with peers

HCM (Nasdaq, USD): plus 2.78 percent, P/E 147.68, market capitalization USD 2.4 billion.

AstraZeneca (Nasdaq, USD): plus 3.34 percent, P/E 25.23, market capitalization USD 259.7 billion.

Bristol-Myers Squibb (NYSE, USD): plus 2.87 percent, P/E 13.43, market capitalization USD 124.6 billion.

Euro price after the Xetra close

The Lang & Schwarz quote places HUTCHMED at EUR 12.35 on October 15, 2026 at 7:39 p.m. CEST, after the Xetra close. The Nasdaq price was USD 13.86 at 1:46 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of HUTCHMED stock.